News

Promacta (eltrombopag) is known as Revolade outside the US and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019. “After extensive

The approval has been granted for Spravato for use in conjunction with an oral antidepressant in adults with TRD, who have cycled through multiple treatments without relief. Janssen

Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood

The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked

The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9%

Also known as RPL554, ensifentrine, is being investigated as an inhaled dual inhibitor of the phosphodiesterase 3 and 4 enzymes and is designed to have bronchodilator and anti-inflammatory

The phase IIIb trial compared Feraccru against Ferinject in 242 inflammatory bowel disease (IBD) patients whose iron deficiency anaemia (IDA) and haemoglobin (Hb) measurements are as low as

Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development

The collaboration leverages Abpro’s proprietary DiversImmuneTM antibody discovery platform. Under  the  terms  of  the  agreement,  Abpro  is  eligible to  receive up  to  $4  billion,  including $60 million  in